Expression of progesterone receptors A and B and insulin-like growth factor-I in human myometrium and fibroids after treatment with a gonadotropin-releasing hormone analogue.
OBJECTIVE
To determine mRNA and protein expression of the progesterone receptor (PR) and insulin-like growth factor-I (IGF-I) in myometrium and fibroids.


METHODS
Retrospective clinical study.


METHODS
Hospital-based and university-affiliated research laboratories.


METHODS
Twelve women in the proliferative phase and six women treated with GnRH analogue (GnRH-a).


METHODS
Blood sampling and collection of myometrium and fibroids.


METHODS
PR and IGF-I mRNA levels in fibroids and myometrium were analyzed by solution hybridization and in situ hybridization whereas the proteins were localized by immunohistochemistry.


RESULTS
Fibroids and myometrium from women in the proliferative phase showed significantly higher PR mRNA than the corresponding tissues from GnRH-a-treated women. The amount of cells positively stained for PR-AB and PR-B in fibroids and myometrium decreased after GnRH-a treatment compared with in the proliferative phase. The IGF-I mRNA in both fibroids and myometrium in the proliferative phase was significantly higher than those after GnRH-a treatment. The immunostaining of IGF-I showed no difference between the two tissues. There was weaker immunostaining in the GnRH-a-treated group compared with in the proliferative phase group.


CONCLUSIONS
The shrinkage of fibroids after steroid deprivation is associated with alterations in PR and IGF-I expression.
Wu
Xuxia
X
Division for Reproductive Endocrinology, Department of Woman and Child Health, Karolinska Institutet, Stockholm, Sweden. xuxia.wu@kbh.ki.se
Wang
Hong
H
Englund
Katarina
K
Blanck
Agneta
A
Lindblom
Bo
B
Sahlin
Lena
L
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D005260:Female; D005498:Follicular Phase / Q000502:physiology; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives*; D017273:Goserelin / Q000627:therapeutic use; D006801:Humans; D007150:Immunohistochemistry; D007334:Insulin-Like Growth Factor I / Q000235:genetics / Q000378:metabolism*; D007889:Leiomyoma / Q000188:drug therapy* / Q000378:metabolism* / Q000503:physiopathology; D008875:Middle Aged; D009215:Myometrium / Q000187:drug effects / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D011980:Receptors, Progesterone / Q000235:genetics / Q000378:metabolism*
D018931:Antineoplastic Agents, Hormonal; D012333:RNA, Messenger; D011980:Receptors, Progesterone; C101118:progesterone receptor A; C097314:progesterone receptor B; D017273:Goserelin; D007987:Gonadotropin-Releasing Hormone; D007334:Insulin-Like Growth Factor I